Takenari Nakagome

This inventor holds 22 USPTO granted patents, primarily in Antibiotic Chemistry. Top assignee: Sumitomo Chemical Company, Limited. Active years: 1976-1983.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takenari Nakagome. Retrieved from https://idiyas.com/inventor/takenari-nakagome

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22

% Patents Active = 100.0

Average Co-Inventor Count = 5.6

ph-index = 9

Forward Citations = 166(Granted Patents)

Location History:

Toyonaka, JA (1976)
Nishinomiya, JA (1976 - 1977)
Hyogo, JA (1977)
Nishinomiya, JP (1978 - 1983)

Company Filing History:

22 out of 6,964

Sumitomo Chemical Company, Limited

patents

Years Active: 1976-1983

Loading Chart...

Areas of Expertise:

Cephalosporins

Penicillins

Antibacterial

Thiazoloquinoline

Peptide Preparation

Naphthyridine

Methoxy Compounds

Heterocyclic Derivatives

Acetamido

Novel Antibiotics

Chemical Synthesis

Pharmaceuticals

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4368198 - Cephalosporins (1983-01-11),

2. 4302454 - Cephalosporins (1981-11-24),

3. 4226863 - 7-Methoxy cephalosporins (1980-10-07),

4. 4165373 - 7-(.alpha.-Acylamino-.alpha.-phenyl or thienylacetamido) cephalosporin (1979-08-21),

5. 4160087 - N-acylamino-.alpha.-arylacetamido cephalosporins (1979-07-03),

6. 4156724 - N-acylamino-alpha-arylacetamido cephalosporins and antibacterial (1979-05-29),

7. 4125611 - 3-Heterocyclic thiomethyl 7-methoxy-7 substituted acetamido (1978-11-14),

8. 4117126 - 7-(.alpha.-(4-Hydroxy-1,5-naphthyridine-3-carbonamido)-.alpha.-ph (1978-09-26),

9. 4061748 - 7-(.alpha.-(4 (1977-12-06),

10. 4054568 - Thiazolo(5,4-f)quinoline-8-carboxylic acid derivatives (1977-10-18),

11. 4046904 - Novel penicillin, and its preparation and use (1977-09-06),

12. 4043991 - Preparation of peptides and cephalosporins (1977-08-23),

13. 4008237 - 2,3,5,8-Tetrahydro-5-alkoxy-8-oxofuro(2,3-g)quinoline-7-carboxylic acid (1977-02-15),

14. 4008220 - Penicillins (1977-02-15),

15. 4005075 - Penicillins and their preparation (1977-01-25),

Title: Innovations in Pharmaceuticals: The Contributions of Takenari Nakagome

Introduction: Takenari Nakagome, a distinguished inventor based in Nishinomiya, Japan, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 22 patents, he has focused primarily on the development of innovative cephalosporins.

Latest Patents: Among his latest patents, Takenari has introduced a novel compound of the formula (I), where A is a monocyclic or polycyclic heteroaromatic ring containing at least one nitrogen atom as a hetero atom. This compound may be unsubstituted or substituted with one or more substituents, showcasing his commitment to advancing medicinal chemistry.

Career Highlights: Takenari Nakagome has been a vital part of Sumitomo Chemical Company, Limited, where he utilizes his expertise in drug development. His innovative approach and dedication have led to important advancements in the pharmaceutical industry, particularly in antibiotic development.

Collaborations: Throughout his career, Takenari has collaborated with notable colleagues, including Toshiaki Komatsu and Hirotada Yamada. These partnerships have allowed for the sharing of knowledge and expertise, contributing to the successful creation of new pharmaceutical compounds.

Conclusion: Takenari Nakagome stands out as a prominent figure in the realm of pharmaceutical innovations. His 22 patents and ongoing work at Sumitomo Chemical Company reflect his dedication to enhancing healthcare through groundbreaking inventions. As the pharmaceutical industry continues to evolve, inventions like Nakagome's will play a crucial role in shaping the future of medicine.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]